287 related articles for article (PubMed ID: 2068099)
1. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.
Hariharan K; Nara PL; Caralli VM; Norton FL; Haigwood N; Kang CY
J Virol; 1993 Feb; 67(2):953-60. PubMed ID: 7678311
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
[TBL] [Abstract][Full Text] [Related]
6. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
7. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates.
Devico A; Silver A; Thronton AM; Sarngadharan MG; Pal R
Virology; 1996 Apr; 218(1):258-63. PubMed ID: 8615032
[TBL] [Abstract][Full Text] [Related]
8. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
Chamat S; Nara P; Berquist L; Whalley A; Morrow WJ; Köhler H; Kang CY
J Immunol; 1992 Jul; 149(2):649-54. PubMed ID: 1378074
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
[TBL] [Abstract][Full Text] [Related]
10. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
11. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
Kang CY; Hariharan K; Posner MR; Nara P
J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
[TBL] [Abstract][Full Text] [Related]
12. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
Moore JP; Ho DD
J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
[TBL] [Abstract][Full Text] [Related]
14. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
[TBL] [Abstract][Full Text] [Related]
15. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
[TBL] [Abstract][Full Text] [Related]
16. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
17. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.
Thali M; Furman C; Wahren B; Posner M; Ho DD; Robinson J; Sodroski J
J Acquir Immune Defic Syndr (1988); 1992; 5(6):591-9. PubMed ID: 1588493
[TBL] [Abstract][Full Text] [Related]
18. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
[TBL] [Abstract][Full Text] [Related]
19. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
20. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
Vogel T; Kurth R; Norley S
J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
